Want to see CGON full AI Analyst Report?
CG Oncology, Inc. (CGON) Stock Statistics & Valuation Metrics
Total Valuation
CG Oncology, Inc. has a market cap or net worth of $5.73B. The enterprise value is $5.25B.
- Market Cap
- $5.73B
- Enterprise Value
- $5.25B
Share Statistics
CG Oncology, Inc. has 88,640,370 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 88,640,370
- Owned by Insiders
- 2.35%
- Owned by Institutions
- 47.69%
Financial Efficiency
CG Oncology, Inc.’s return on equity (ROE) is -0.21 and return on invested capital (ROIC) is -25.05%.
- Return on Equity (ROE)
- -0.21
- Return on Assets (ROA)
- -0.20
- Return on Invested Capital (ROIC)
- -25.05%
- Return on Capital Employed (ROCE)
- -0.25
- Revenue Per Employee
- 28.45K
- Profits Per Employee
- -1.13M
- Employee Count
- 142
- Asset Turnover
- 0.01
- Inventory Turnover
- 2.97
Valuation Ratios
The current PE Ratio of CG Oncology, Inc. is -23.96. CG Oncology, Inc.’s PEG ratio is 0.63.
- PE Ratio
- -23.96
- PS Ratio
- 920.56
- PB Ratio
- 5.54
- Price to FCF
- -31.97
- Price to Operating Cash Flow
- -31.97
- PEG Ratio
- 0.63
Income Statement
In the last 12 months, CG Oncology, Inc. had revenue of 4.04M and earned -161.00M in profits. Earnings per share was -2.08.
- Revenue
- 4.04M
- Gross Profit
- -607.00K
- Operating Income
- -190.77M
- Pretax Income
- -161.00M
- Net Income
- -161.00M
- EBITDA
- -159.55M
- Earnings Per Share (EPS)
- -2.08
Cash Flow
In the last 12 months, operating cash flow was -178.47M and capital expenditures -876,000, giving a free cash flow of -179.34M billion.
- Operating Cash Flow
- -178.47M
- Free Cash Flow
- -179.34M
- Free Cash Flow per Share
- -2.03
Dividends & Yields
CG Oncology, Inc. pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -3.13%
- Earnings Yield
- -3.93%
Stock Price Statistics
- Beta
- 1.76
- 52-Week Price Change
- 52.30%
- 50-Day Moving Average
- 69.33
- 200-Day Moving Average
- 66.13
- Relative Strength Index (RSI)
- 49.12
- Average Volume (3m)
- 872.88K
Important Dates
CG Oncology, Inc. upcoming earnings date is Nov 12, 2026, TBA (Not Confirmed).
- Last Earnings Date
- Aug 06, 2026
- Next Earnings Date
- Nov 12, 2026
- Ex-Dividend Date
- ―
Financial Position
CG Oncology, Inc. as a current ratio of 24.63, with Debt / Equity ratio of 0.93%
- Current Ratio
- 24.63
- Quick Ratio
- 24.58
- Debt to Market Cap
- 0.00
- Net Debt to EBITDA
- 0.16
- Interest Coverage Ratio
- 0.00
Taxes
In the past 12 months, CG Oncology, Inc. has paid 0 in taxes.
- Income Tax
- 0
- Effective Tax Rate
- 0.00
Enterprise Valuation
CG Oncology, Inc. EV to EBITDA ratio is -25.84, with an EV/FCF ratio of -31.91.
- EV to Sales
- 918.83
- EV to EBITDA
- -25.84
- EV to Free Cash Flow
- -31.91
- EV to Operating Cash Flow
- -32.06
Balance Sheet
CG Oncology, Inc. has $1.03B in cash and marketable securities with $8.82M in debt, giving a net cash position of $1.02B billion.
- Cash & Marketable Securities
- $1.03B
- Total Debt
- $8.82M
- Net Cash
- $1.02B
- Net Cash Per Share
- $11.50
- Tangible Book Value Per Share
- $11.55
Margins
Gross margin is -82.69%, with operating margin of -4056.18%, and net profit margin of -3602.68%.
- Gross Margin
- -82.69%
- Operating Margin
- -4056.18%
- Pretax Margin
- -3602.68%
- Net Profit Margin
- -3602.68%
- EBITDA Margin
- -3555.22%
- EBIT Margin
- -3602.68%
Analyst Forecast
The average price target for CG Oncology, Inc. is $92.30, which is 11.43% higher than the current price. The consensus rating is Strong Buy
- Price Target
- $92.30
- Price Target Upside
- 42.70% Upside
- Analyst Consensus
- Strong Buy
- Analyst Count
- 11
- Revenue Growth Forecast
- 1030.31%
- EPS Growth Forecast
- -60.33%
Scores
- Smart Score
- 3
- AI Score
- 60
